Anavex Life Sciences Corp (AVXL)

[sokol]

I believe the decision to discontinue any other therapy of any patient participant in this or any trial must be a decision made by each patient and the patient's physician. Furthermore, it may be that this would need to be reported to the FDA. It is questionable whether anyone that is not the patient's physician would recommend that the patient discontinue an FDA approved drug prescribed by the patient's physician and take instead a mono-therapy that has not been approved by the FDA. I see serious implications in pursuing the path of "switching" a patient to an unapproved mono-therapy -- "efficacy" has not been established! Anavex would, in my opinion, be foolish to "switch" patients to the mono-therapy and announce it to the world as you say. Frankly, I do not think Anavex can legally do that. Moreover, I do not think a physician would risk "switching" a patient from an approved drug (SOC) to an unapproved drug!